These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38378950)

  • 1. Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.
    Wang HY; Li L; Nelson CS; Barfield R; Valencia S; Chan C; Muramatsu H; Lin PJC; Pardi N; An Z; Weissman D; Permar SR
    NPJ Vaccines; 2024 Feb; 9(1):38. PubMed ID: 38378950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
    Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
    J Infect Dis; 2024 Aug; 230(2):455-466. PubMed ID: 38324766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
    Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection.
    Valencia SM; Rochat E; Harnois MJ; Dennis M; Webster HS; Hora B; Kumar A; Wang HS; Li L; Freed D; Zhang N; An Z; Wang D; Permar SR
    NPJ Vaccines; 2023 Oct; 8(1):154. PubMed ID: 37816743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
    Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
    EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
    Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
    Gomes AC; Baraniak IA; McIntosh MR; Sodi I; Langstone T; Siddiqui S; Atkinson C; McLean GR; Griffiths PD; Reeves MB
    J Gen Virol; 2023 Jun; 104(6):. PubMed ID: 37310000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
    Jenks JA; Nelson CS; Roark HK; Goodwin ML; Pass RF; Bernstein DI; Walter EB; Edwards KM; Wang D; Fu TM; An Z; Chan C; Permar SR
    Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
    Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
    Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
    Gerna G; Lilleri D
    New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles.
    Curtsinger JM; Liu YN; Radeke R; Bryon MK; Fuad S; Bach FH; Gehrz RC
    J Gen Virol; 1994 Feb; 75 ( Pt 2)():301-7. PubMed ID: 8113751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.
    Reuter N; Kropff B; Schneiderbanger JK; Alt M; Krawczyk A; Sinzger C; Winkler TH; Britt WJ; Mach M; Thomas M
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.
    Choi KY; El-Hamdi NS; McGregor A
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33729125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.